# Clinical Core

> **NIH NIH P30** · YALE UNIVERSITY · 2021 · $785,944

## Abstract

SUMMARY OF THE CLINICAL CORE
The over-arching goal of the Core will be to provide research diagnostic evaluations for a large clinical
population with a special emphasis on participants who are followed longitudinally and tracked to autopsy to
provide well-characterized participants for the research projects conducted by ADRC investigators and
collaborators. Important focuses of the Clinical Core—as for the Yale ADRC broadly—include cellular
neuroscience, synaptic mechanisms, and an emphasis on systematic storage of biospecimens for current and
future biomarker studies. The importance of neuroimaging and fluid biomarkers for AD diagnosis and
therapeutic development is increasing well appreciated, and recent research has emphasized the importance
of classifying patients according to the presence of β-amyloid deposition, pathologic tau, and
neurodegeneration (ATN). The Yale ADRC Imaging, Biomarker, and Neuropathology Cores and specific
Developmental Projects will seek to develop these methods with relevance to AD and related disorders. In
partnership with these efforts, the Clinical Core will undertake the collection of a wide range of imaging studies
and fluid biomarker specimens across the full spectrum of AD cross-sectionally and during the full course of
AD longitudinally. Aim 1 will maintain the Core Population through enrollment of 250 new participants on the
full continuum of AD (from preclinical to dementia), as well as non-AD dementias and normal controls. Aim 2
will enroll these participants in the Uniform Data Set (UDS) population and make the UDS measures available
to the National Alzheimer’s Coordinating Center (NACC) for national studies. Aim 3 will enroll subjects into the
Autopsy Program. Aim 4 will provide appropriate subjects for the clinical studies affiliated with the ADRC. Aim
5 will collect biological specimens for Yale ADRC and other researchers for biomarker studies. Aim 6 will assist
the Research Education Core in training future clinical and translational researchers in AD and related
disorders. These Aims will provide ADRC affiliated investigators the ready ability to test biomarkers—once
validated in AD dementia—in the earliest stages of AD pathogenesis.

## Key facts

- **NIH application ID:** 10180853
- **Project number:** 5P30AG066508-02
- **Recipient organization:** YALE UNIVERSITY
- **Principal Investigator:** CHRISTOPHER H VAN DYCK
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $785,944
- **Award type:** 5
- **Project period:** 2020-06-15 → 2025-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10180853

## Citation

> US National Institutes of Health, RePORTER application 10180853, Clinical Core (5P30AG066508-02). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10180853. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*